333:
493:
the growing adoption of EHRs, claims data, patient registries, and mHealth technologies provides a robust foundation for RWE. Continued efforts to build capacity, foster collaboration, and address ethical considerations will further strengthen the role of RWE in improving healthcare outcomes across Latin
America.
492:
Real World
Evidence studies are becoming increasingly important in the Latin American region, offering valuable insights that support healthcare decision-making, policy development, and drug safety monitoring. Despite challenges related to data quality, standardization, and regulatory complexities,
474:
Developing expertise in RWE methodologies is crucial for the growth of RWE studies in Latin
America. Capacity building initiatives, including training programs and workshops, can equip researchers, clinicians, and policymakers with the skills needed to conduct robust RWE studies and interpret their
378:
RWE is instrumental in monitoring drug safety and effectiveness post-approval. In Latin
America, pharmacovigilance efforts benefit from RWE by identifying adverse drug reactions and long-term safety concerns in diverse patient populations. This is critical for ensuring the ongoing safety of medical
465:
RWE studies must adhere to ethical and regulatory standards to protect patient privacy and ensure data security. Latin
American countries have diverse regulatory environments, and navigating these can be complex. Establishing clear guidelines and fostering collaboration among stakeholders can help
456:
One of the primary challenges in conducting RWE studies in Latin
America is ensuring the quality and standardization of RWD. Variations in data collection methods, incomplete records, and inconsistent reporting can affect the reliability of RWE. Efforts to harmonize data standards and improve data
392:
EHRs are a vital source of RWD in Latin
America. They provide comprehensive patient data, including medical history, diagnoses, treatments, and outcomes. Countries like Brazil, Mexico, and Argentina have made significant progress in implementing EHR systems, facilitating the collection of valuable
346:
Real World
Evidence (RWE) refers to the clinical evidence regarding the usage and potential benefits or risks of a medical product/service derived from analysis of real-world data (RWD). This includes data from prospective interviews with patients and healthcare professionals, sources like health
410:
Disease-specific and product-specific registries collect detailed information on patients, treatments, and outcomes. Registries are particularly useful for studying rare diseases and long-term treatment effects. Latin
American countries have established various registries to support RWE studies,
483:
Collaboration among countries, institutions, and healthcare providers is key to advancing RWE in Latin
America. Sharing data and best practices can enhance the quality and impact of RWE studies. Regional partnerships and networks can facilitate data sharing and foster a collaborative research
369:
Governments and regulatory bodies in Latin America increasingly rely on RWE to inform policy decisions. This includes the approval and reimbursement of new treatments, assessment of healthcare interventions, and development of public health strategies. By leveraging RWE, policymakers can make
419:
The increasing adoption of mHealth technologies and wearable devices in Latin America provides new avenues for collecting patient-generated data. These technologies enable continuous monitoring of health parameters, patient-reported outcomes, and lifestyle factors, enriching the pool of
360:
RWE plays a crucial role in healthcare decision-making by providing evidence that complements data from randomized controlled trials (RCTs). This is particularly important in Latin America, where healthcare systems face unique challenges such as diverse populations, varying healthcare
347:
records, insurance and billing records, patient generated data including wearables and in-app data. In Latin America, the application and development of RWE studies have gained momentum, providing valuable insights into healthcare practices, patient outcomes, and policy-making.
401:
Healthcare claims and billing records offer insights into treatment patterns, healthcare utilization, and costs. This data is essential for understanding the economic impact of healthcare interventions and identifying trends in healthcare delivery across the region.
361:
infrastructures, and economic constraints. RWE helps bridge the gap between clinical trial results and everyday clinical practice, offering insights into the effectiveness and safety of treatments in real-world settings.
443:
Most of the countries in the region do not have adequate infrastructure like patient registries, interoperable EHRs or access to EHRs for any public research. Hence the likely solution would be to conduct
578:
230:
tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the
268:
573:
568:
501:
282:
164:
188:
75:
246:
445:
59:
176:
63:
48:
516:
182:
132:
99:
502:
https://www.linkedin.com/pulse/addressing-unique-challenges-retrospective-n60mc/?trackingId=ZFGD7Ih7JVJ7tkCXsVtPaA%3D%3D
209:
136:
from experienced editors. These venues are only for help with editing and the submission process, not to get reviews.
52:
213:
194:
86:
If you have not resolved the issues listed above, your draft will be declined again and potentially deleted.
44:
83:
If you would like to continue working on the submission, click on the "Edit" tab at the top of the window.
272:
227:
148:
515:
García Martí, Sebastián; Pichón-Riviere, Andrés; Augustovski, Federico; Espinoza, Manuel (2023).
544:
536:
300:
528:
29:
421:
144:
216:
to find examples of Knowledge's best writing on topics similar to your proposed article.
411:
contributing to a better understanding of disease epidemiology and treatment efficacy.
106:
Please do not remove reviewer comments or this notice until the submission is accepted.
71:
517:"Real-world evidence: experiences and challenges for decision making in Latin America"
562:
170:
151:. Some WikiProjects are more active than others so a speedy reply is not guaranteed.
201:
198:
67:
36:
332:
323:
Please note that if the issues are not fixed, the draft will be declined again.
143:, or if the review is taking a lot of time, you can try asking for help on the
532:
540:
548:
62:
than an encyclopedia article. Submissions should summarise information in
370:
informed decisions that improve healthcare quality and accessibility.
226:
To improve your odds of a faster review, tag your draft with relevant
15:
521:
International Journal of Technology Assessment in Health Care
428:
Challenges with the above sources in Latin American Countries
379:
products and maintaining public trust in healthcare systems.
331:
292:
24:
579:
AfC submissions on science, mathematics and engineering
457:
quality are essential for maximizing the value of RWE.
315:
304:
124:
91:
446:prospective data collection from patients and HCPs
47:. If you need help with referencing, please see
43:sources are required so that information can be
343:Evidence based health research in Latin America
35:This submission is not adequately supported by
22:Submission declined on 24 June 2024 by
8:
415:Mobile Health (mHealth) and Wearable Devices
167:– a basic overview on how to edit Knowledge.
448:. Besides this, the other challenges are
507:
222:Improving your odds of a speedy review
70:. Please write about the topic from a
574:Draft articles on medicine and health
461:Ethical and Regulatory Considerations
7:
569:AfC submissions by date/24 June 2024
165:Knowledge:Contributing to Knowledge
58:This submission reads more like an
351:Importance of RWE in Latin America
197:– make sure your article includes
14:
383:Potential Sources of RWD globally
374:Drug Safety and Pharmacovigilance
189:Knowledge:Writing better articles
452:Data Quality and Standardization
388:Electronic Health Records (EHRs)
120:editing or submitting your draft
89:If you need extra help, please
479:Collaboration and Data Sharing
470:Capacity Building and Training
177:Help:Referencing for beginners
1:
191:– how to improve your article
185:– how to develop your article
183:Knowledge:Article development
130:at the AfC Help Desk or get
97:at the AfC Help Desk or get
66:and not contain opinions or
210:Knowledge:Featured articles
179:– how to include references
64:secondary, reliable sources
595:
466:address these challenges.
356:Healthcare Decision-Making
533:10.1017/S0266462323002647
303:3 seconds ago. Reviewer:
103:from experienced editors.
49:Referencing for beginners
397:Claims and Billing Data
214:Knowledge:Good articles
195:Knowledge:Verifiability
173:– how to use the markup
475:findings effectively.
336:
249:Add tags to your draft
158:How to improve a draft
141:feedback on your draft
393:RWD for RWE studies.
335:
72:neutral point of view
208:You can also browse
149:relevant WikiProject
202:third-party sources
76:encyclopedic manner
406:Patient Registries
365:Policy Development
337:
296: 3 months ago.
424:for RWE studies.
341:
340:
327:
326:
308:
297:
290: Declined by
126:ask us a question
118:If you need help
113:Where to get help
93:ask us a question
68:original research
586:
553:
552:
512:
440:
439:
435:
320:
318:
311:
310:
298:
295:
289:
259:Editor resources
253:
251:
240:Women scientists
129:
96:
37:reliable sources
33:
27:
16:
594:
593:
589:
588:
587:
585:
584:
583:
559:
558:
557:
556:
514:
513:
509:
499:
490:
481:
472:
463:
454:
441:
437:
433:
431:
430:
417:
408:
399:
390:
385:
376:
367:
358:
353:
344:
328:
316:
314:
299:Last edited by
291:
288:
287:
260:
256:
255:
254:
247:
245:
223:
219:
218:
206:
159:
155:
154:
123:
114:
110:
109:
90:
79:
56:
23:
21:
12:
11:
5:
592:
590:
582:
581:
576:
571:
561:
560:
555:
554:
506:
505:
498:
495:
489:
486:
480:
477:
471:
468:
462:
459:
453:
450:
429:
426:
416:
413:
407:
404:
398:
395:
389:
386:
384:
381:
375:
372:
366:
363:
357:
354:
352:
349:
342:
339:
338:
329:
325:
324:
321:
309:
286:
285:
261:
258:
257:
244:
224:
221:
220:
205:
204:
192:
186:
180:
174:
168:
161:
160:
157:
156:
153:
152:
137:
115:
112:
111:
108:
107:
104:
87:
84:
80:
57:
53:Citing sources
34:
19:
13:
10:
9:
6:
4:
3:
2:
591:
580:
577:
575:
572:
570:
567:
566:
564:
550:
546:
542:
538:
534:
530:
526:
522:
518:
511:
508:
504:
503:
496:
494:
487:
485:
484:environment.
478:
476:
469:
467:
460:
458:
451:
449:
447:
436:
427:
425:
423:
414:
412:
405:
403:
396:
394:
387:
382:
380:
373:
371:
364:
362:
355:
350:
348:
334:
330:
322:
319:
313:
312:
306:
305:Inform author
302:
294:
284:
283:Fix bare URLs
281:
278:
274:
270:
266:
263:
262:
252:
250:
243:
241:
237:
233:
229:
217:
215:
211:
203:
200:
196:
193:
190:
187:
184:
181:
178:
175:
172:
171:Help:Wikitext
169:
166:
163:
162:
150:
146:
142:
138:
135:
134:
128:
127:
121:
117:
116:
105:
102:
101:
95:
94:
88:
85:
82:
81:
77:
73:
69:
65:
61:
54:
50:
46:
42:
38:
31:
26:
20:
18:
17:
524:
520:
510:
500:
491:
482:
473:
464:
455:
442:
418:
409:
400:
391:
377:
368:
359:
345:
301:Citation bot
279:
276:
269:Citation bot
264:
248:
239:
235:
231:
225:
207:
140:
139:If you need
131:
125:
119:
98:
92:
40:
228:WikiProject
563:Categories
527:(1): e73.
497:References
488:Conclusion
265:Easy tools
541:0266-4623
280:Advanced:
236:Astronomy
232:Biography
145:talk page
133:live help
122:, please
100:live help
549:38108157
317:Resubmit
199:reliable
45:verified
41:Reliable
271: (
547:
539:
432:": -->
293:Liance
242:tags.
238:, and
74:in an
25:Liance
147:of a
60:essay
545:PMID
537:ISSN
434:edit
273:help
212:and
51:and
30:talk
529:doi
422:RWD
565::
543:.
535:.
525:39
523:.
519:.
275:)
267::
234:,
39:.
32:).
551:.
531::
438:]
307:.
277:|
78:.
55:.
28:(
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.